Apricus Biosciences Receives European Marketing Approval for VitarosTuesday, June 11, 2013
Apricus Biosciences Receives European Marketing Approval for Vitaros
San Diego-based Apricus Biosciences Inc. has received European marketing approval for its drug Vitaros, which treats erectile dysfunction.
It has partnered with Sandoz, a subsidiary of Swiss drug giant Novartis AG, and Italian pharma company Bracco SpA to sell Vitaros in several countries in Europe
Japanese drugmaker Takeda Pharmaceutical Co. Ltd. will distribute the drug in Canada.
The company recently received $17.1 million in financing through a secondary public offering, and plans to use the funds to advance the production of Vitaros and a sexual dysfunction drug for women called Femprox.
Apricus does not have production or marketing rights in America — it sold the U.S. marketing rights for the drug to Rockaway, New Jersey-based Warner Chilcott PLC for $2.5 million in 2008.
— Meghana Keshavan